Targeting PYK2, entrectinib allays anterior subcapsular cataracts in mice by regulating TGFβ2 signaling pathway
Targeting with PYK2, Entrectinib can block TGF-β2/Smad and TGF-β2/non-Smad signaling pathways, lessen the activation of EMT, and alleviate fibrosis cataract. Entrectinib may be a potential treatment for fibrosis cataract in clinic.
Authors
- Yuxuan Jia (ORCID: https://orcid.org/0009-0006-4267-1656)
- Xudong Song (ORCID: https://orcid.org/0000-0002-8036-5936)
- Yayue Hu
- Peilin Yue
- Xuefei Ding (ORCID: https://orcid.org/0000-0001-5737-0422)
- Rui Fang
- Xiaohe Li (ORCID: https://orcid.org/0000-0003-1552-6243)
- Enjie Li
- Honggang Zhou
Institutions
- Beijing Tongren Hospital (CN)
- Capital Medical University (CN)
- Nankai University (CN)
- State Key Laboratory of Medicinal Chemical Biology
Publication Details
- Journal
- Molecular Medicine
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s10020-024-00921-9
- Citations
- 3
- Primary Topic
- Protease and Inhibitor Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.86
Funders
- National Natural Science Foundation of China